Literature DB >> 23774208

DDB2: a novel regulator of NF-κB and breast tumor invasion.

Marie Ennen1, Rémi Klotz, Nadège Touche, Sophie Pinel, Claire Barbieux, Vanessa Besancenot, Emilie Brunner, Denise Thiebaut, Alain C Jung, Sonia Ledrappier, Lionel Domenjoud, Joseph Abecassis, François Plénat, Stéphanie Grandemange, Philippe Becuwe.   

Abstract

The DNA repair protein damaged DNA-binding 2 (DDB2) has been implicated in promoting cell-cycle progression by regulating gene expression. DDB2 is selectively overexpressed in breast tumor cells that are noninvasive, but not in those that are invasive. We found that its overexpression in invasive human breast tumor cells limited their motility and invasiveness in vitro and blocked their ability to colonize lungs in vivo, defining a new function for DDB2 in malignant progression. DDB2 overexpression attenuated the activity of NF-κB and the expression of its target matrix metalloprotease 9 (MMP9). Mechanistic investigations indicated that DDB2 decreased NF-κB activity by upregulating expression of IκBα by binding the proximal promoter of this gene. This effect was causally linked to invasive capacity. Indeed, knockdown of DDB2-induced IκBα gene expression restored NF-κB activity and MMP9 expression, along with the invasive properties of breast tumor cells overexpressing DDB2. Taken together, our findings enlighten understanding of how breast cancer cells progress to an invasive phenotype and underscore potential clinical interest in DDB2 as a prognostic marker or therapeutic target in this setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23774208     DOI: 10.1158/0008-5472.CAN-12-3655

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Inhibition of miR-328-3p Impairs Cancer Stem Cell Function and Prevents Metastasis in Ovarian Cancer.

Authors:  Amit K Srivastava; Ananya Banerjee; Tiantian Cui; Chunhua Han; Shurui Cai; Lu Liu; Dayong Wu; Ri Cui; Zaibo Li; Xiaoli Zhang; Guozhen Xie; Karuppaiyah Selvendiran; Srinivas Patnaik; Adam R Karpf; Jinsong Liu; David E Cohn; Qi-En Wang
Journal:  Cancer Res       Date:  2019-03-20       Impact factor: 12.701

2.  A DDB2 mutant protein unable to interact with PCNA promotes cell cycle progression of human transformed embryonic kidney cells.

Authors:  Paola Perucca; Sabrina Sommatis; Roberto Mocchi; Ennio Prosperi; Lucia Anna Stivala; Ornella Cazzalini
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Expression of DDB2 Protein in the Initiation, Progression, and Prognosis of Colorectal Cancer.

Authors:  Huaiwei Yang; Jingwei Liu; Jingjing Jing; Zeyang Wang; Yi Li; Kaihua Gou; Xue Feng; Yuan Yuan; Chengzhong Xing
Journal:  Dig Dis Sci       Date:  2018-07-27       Impact factor: 3.199

4.  DDB2 increases radioresistance of NSCLC cells by enhancing DNA damage responses.

Authors:  Ning Zou; Guozhen Xie; Tiantian Cui; Amit Kumar Srivastava; Meihua Qu; Linlin Yang; Shaozhong Wei; Yanfang Zheng; Qi-En Wang
Journal:  Tumour Biol       Date:  2016-08-23

Review 5.  A protein with broad functions: damage-specific DNA-binding protein 2.

Authors:  Ning Bao; Jiguang Han; Huimin Zhou
Journal:  Mol Biol Rep       Date:  2022-10-03       Impact factor: 2.742

6.  DDB2 suppresses tumorigenicity by limiting the cancer stem cell population in ovarian cancer.

Authors:  Chunhua Han; Ran Zhao; Xingluo Liu; Amit Srivastava; Li Gong; Hsiaoyin Mao; Meihua Qu; Weiqiang Zhao; Jianhua Yu; Qi-En Wang
Journal:  Mol Cancer Res       Date:  2014-02-26       Impact factor: 5.852

7.  DDB2 Is a Novel Regulator of Wnt Signaling in Colon Cancer.

Authors:  Shuo Huang; Damiano Fantini; Bradley J Merrill; Srilata Bagchi; Grace Guzman; Pradip Raychaudhuri
Journal:  Cancer Res       Date:  2017-10-11       Impact factor: 12.701

8.  NER-factor DDB2 regulates HIF1α and hypoxia-response genes in HNSCC.

Authors:  Prashant V Bommi; Vaibhav Chand; Nishit K Mukhopadhyay; Pradip Raychaudhuri; Srilata Bagchi
Journal:  Oncogene       Date:  2019-11-18       Impact factor: 9.867

9.  From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression.

Authors:  Clémence Chamard-Jovenin; Alain C Jung; Amand Chesnel; Joseph Abecassis; Stéphane Flament; Sonia Ledrappier; Christine Macabre; Taha Boukhobza; Hélène Dumond
Journal:  BMC Syst Biol       Date:  2015-06-17

10.  Chromatin retention of DNA damage sensors DDB2 and XPC through loss of p97 segregase causes genotoxicity.

Authors:  Marjo-Riitta Puumalainen; Davor Lessel; Peter Rüthemann; Nina Kaczmarek; Karin Bachmann; Kristijan Ramadan; Hanspeter Naegeli
Journal:  Nat Commun       Date:  2014-04-28       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.